Regular ArticleTamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report☆,☆☆,★
Cited by (0)
- ☆
Address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107.
- ☆☆
This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).
- ★
The following Gynecologic Oncology Group institutions participated in this study: University of Alabama at Birmingham, The Oregon Health Sciences Center University, Duke University Medical Center, Temple University Health Science Center Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, University of Minnesota Medical School, Colorado Foundation for Medical Care, University of California Medical Center at Los Angeles, University of Miami School of Medicine, Georgetown University Hospital, University of Iowa Hospitals and Clinics, Indiana University Medical Center, Bowman Gray School of Medicine of Wake Forest University, The Albany Medical College of Union University, University of California Medical Center at Irvine, Illinois Cancer Council, University of Pittsburgh School of Medicine, St. Louis University Medical Center, Jacksonville University Hospital, Latter Day Saints Hospital, Eastern Virginia Medical School, University of New Mexico Cancer Research and Treatment Center, Cleveland Clinic Foundation, State University of New York at Stony Brook, and Pennsylvania Hospital.